Skip to main content
Erschienen in: International Journal of Hematology 6/2018

24.08.2018 | Case Report

KMT2A-rearranged infantile acute myeloid leukemia masquerading as juvenile myelomonocytic leukemia

verfasst von: Takuyo Kanayama, Toshihiko Imamura, Yasuhiro Kawabe, Shinya Osone, Junko Tahara, Fuminori Iwasaki, Naoyuki Miyagawa, Hiroaki Goto, Shinsaku Imashuku, Hajime Hosoi

Erschienen in: International Journal of Hematology | Ausgabe 6/2018

Einloggen, um Zugang zu erhalten

Abstract

Mixed lineage leukemia [MLL; now known as lysine methyltransferase 2A (KMT2A)] rearrangement-positive acute myeloid leukemia (AML) and juvenile myelomonocytic leukemia (JMML) are distinct diseases, although age of susceptibility (infancy or early childhood) and abnormal monocytosis are common clinical features. Here, we report two cases of KMT2A-rearranged infantile AML masquerading as JMML at initial presentation. Both cases showed leukocytosis accompanied by atypical monocytosis. However, in both cases, leukemic blasts were absent at the initial examination. Thus, a diagnosis of JMML was suspected. However, initial cytogenetic analysis revealed that both cases had an 11q23 rearrangement, which is atypical in JMML. Eventually, due to the emergence of leukemic blasts and further cytogenetic studies, both cases were diagnosed with infantile AML with a KMT2A rearrangement. Although one patient remains in complete remission after the completion of AML appropriate chemotherapy, the other died of AML due to treatment failure. Our experience suggests that AML with KMT2A rearrangement should be considered for the differential diagnosis of infantile cases with atypical monocytosis suggestive of JMML. Cytogenetic studies, including fluorescence in situ hybridization analysis of KMT2A, may be helpful in distinguishing between AML with KMT2A rearrangement and JMML.
Literatur
1.
Zurück zum Zitat Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, et al. The Importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. Blood. 1998;92:2322–33.PubMed Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, et al. The Importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. Blood. 1998;92:2322–33.PubMed
2.
Zurück zum Zitat Balgobind BV, Raimondi SC, Harbott J, Zimmermann M, Alonzo TA, Auvrignon A, et al. Novel prognostic subgroups in childhood 11q23/MLL-rearranged acutemyeloid leukemia: results of an international retrospective study. Blood. 2009;114:2489–96.CrossRef Balgobind BV, Raimondi SC, Harbott J, Zimmermann M, Alonzo TA, Auvrignon A, et al. Novel prognostic subgroups in childhood 11q23/MLL-rearranged acutemyeloid leukemia: results of an international retrospective study. Blood. 2009;114:2489–96.CrossRef
3.
Zurück zum Zitat Meyer C, Kowarz E, Hofmann J, Renneville A, Zuna J, Trka J, et al. New insights to the MLL recombinome of acute leukemias. Leukemia. 2009;23:1490–9.CrossRef Meyer C, Kowarz E, Hofmann J, Renneville A, Zuna J, Trka J, et al. New insights to the MLL recombinome of acute leukemias. Leukemia. 2009;23:1490–9.CrossRef
4.
Zurück zum Zitat Swansbury GJ, Slater R, Bain BJ, Moorman AV, Secker-Walker LM. Hematological malignancies with t(9;11)(p21-22;q23)—a laboratory and clinical study of 125 cases. European 11q23 Workshop participants. Leukemia. 1998;12:792–800.CrossRef Swansbury GJ, Slater R, Bain BJ, Moorman AV, Secker-Walker LM. Hematological malignancies with t(9;11)(p21-22;q23)—a laboratory and clinical study of 125 cases. European 11q23 Workshop participants. Leukemia. 1998;12:792–800.CrossRef
5.
Zurück zum Zitat Aricò M, Biondi A, Pui CH. Juvenile myelomonocytic leukemia Blood. 1997;90:479–88.PubMed Aricò M, Biondi A, Pui CH. Juvenile myelomonocytic leukemia Blood. 1997;90:479–88.PubMed
6.
Zurück zum Zitat Locatelli F, Neimeyer CM. How I treat juvenile myelomonocytic leukemia. Blood. 2015;125:1083–90.CrossRef Locatelli F, Neimeyer CM. How I treat juvenile myelomonocytic leukemia. Blood. 2015;125:1083–90.CrossRef
7.
Zurück zum Zitat Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, Bloomfield CD, Cazzola M, Vardiman JW. The 2016 revision to the World. Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391–406.CrossRef Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, Bloomfield CD, Cazzola M, Vardiman JW. The 2016 revision to the World. Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391–406.CrossRef
8.
Zurück zum Zitat Tsukimoto I, Tawa A, Horibe K, Tabuchi K, Kigasawa H, Tsuchida M, et al. Risk-stratified therapy and the intensive use of cytarabine improves the outcome in childhood acute myeloid leukemia: the AML99 trial from the Japanese childhood AML Cooperative Study Group. J Clin Oncol. 2009;27:4007–13.CrossRef Tsukimoto I, Tawa A, Horibe K, Tabuchi K, Kigasawa H, Tsuchida M, et al. Risk-stratified therapy and the intensive use of cytarabine improves the outcome in childhood acute myeloid leukemia: the AML99 trial from the Japanese childhood AML Cooperative Study Group. J Clin Oncol. 2009;27:4007–13.CrossRef
Metadaten
Titel
KMT2A-rearranged infantile acute myeloid leukemia masquerading as juvenile myelomonocytic leukemia
verfasst von
Takuyo Kanayama
Toshihiko Imamura
Yasuhiro Kawabe
Shinya Osone
Junko Tahara
Fuminori Iwasaki
Naoyuki Miyagawa
Hiroaki Goto
Shinsaku Imashuku
Hajime Hosoi
Publikationsdatum
24.08.2018
Verlag
Springer Japan
Erschienen in
International Journal of Hematology / Ausgabe 6/2018
Print ISSN: 0925-5710
Elektronische ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-018-2522-3

Weitere Artikel der Ausgabe 6/2018

International Journal of Hematology 6/2018 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.